



Contact: Rehab AlJamal-Naylor
Tel. 017919-621 733
Email: r.aljamal.naylor@avipero.com

FOR IMMEDIATE PRESS RELEASE

Tuesday, 28 May 2013.

Graham Bell appointed as CEO of AVIPERO.

EDINBURGH, SCOTLAND-Tue, 28 May, 2013-----The board of AVIPERO (Registered in Scotland SC353945) announced today Dr. Graham Bell has been appointed as Chief Executive Officer. Graham has over 25 years experience working in SME in UK, in drug development, business and corporate development roles. Dr Bell is a recognized authority in stratified medicine, having recently served as the Lead Specialist with the UK government's Technology Strategy Board (TSB), Stratified Medicine Innovation Platform. He developed the strategy for future Government investments (up to £50m of TSB investment plus partner organisation investments) and formulated a technology roadmap along with UK stakeholders.

The Director of AVIPERO, Prof. Robert J. Naylor, said: "Graham brings a wealth of experience to AVIPERO with strong track record in the biotech industry through his experience at companies such as Biocure and Cyclacel amongst others. This is in addition to his scientific background in the production of human monoclonal antibodies making him the right person to lead AVIPERO".

About AVIPERO Ltd.

AVIPERO Ltd (Registered in Scotland SC353945) is a private biopharmaceutical company established in 2009. Avipero is focused on the development of novel therapeutics for unmet clinical needs, characterised by a loss of cells and tissues. This includes conditions such as Parkinson's disease (PD), chronic obstructive pulmonary disease (COPD), arthritis and age related cell decline. AVIPERO has a proprietary first-in-class therapeutic platform covered by a strong intellectual property portfolio.

Forward Looking Statements

Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management's outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, AVIPERO's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which AVIPERO may develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and AVIPERO's dependence on collaborative partners and contract research organizations. These factors should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements. Similarly, nothing in this press release is meant to promote a pharmaceutical product or make a regulated claim of efficacy.

FOR FURTHER INFORMATION PLEASE CONTACT:

Dr. Rehab AlJamal-Naylor
AVIPERO Ltd
Director,
07919-621-733
info@avipero.com

